PRKN and hepatocellular carcinoma: Indeed, loss of heterozygosity and copy number of Parkin has been observed in many types of cancers, such as breast, lung, colorectal, and ovarian cancers, hepatocellular carcinoma, non-small-cell lung carcinoma, and lymphomas24–26.